Cancer screening

October 19, 2020
TMIST accrual bar graph

TMIST Breast Cancer Screening Trial Rebounds from COVID-19 Shutdown of Cancer Screenings

October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
June 10, 2020

The Value of TMIST Compared to Other Breast Cancer Screening Studies

TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
February 28, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, February 2020

January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
January 14, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, December 2019/January 2020

Reflecting on key milestones in 2019: TMIST breast cancer screening trial continues to ramp up; NCORP grant renewal emphasizes screening, symptom control, and cancer care delivery research; new role for Dr. Al Benson; E1912's practice-changing trial results; update on Dr. Otis Brawley's efforts to form the Social Determinants of Health Working Group; EA launches the Comis Symposium